The purpose of this study is to characterize the absorption, metabolism, and excretion of carbon 14-labeled temozolomide (C-TMZ) administered p.o. to adult patients with advanced solid malignancies. On day 1 of cycle 1, six patients received a single oral 200-mg dose of C-TMZ (70.2 mCi). Whole blood, plasma, urine, and feces were collected from days 1–8 and on day 14 of cycle 1. Total radioacti...